Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 


Topoisomerase inhibitor. p53 activator.
BML-GR307-0100 100 mg 114.00 USD
BML-GR307-0500 500 mg 462.00 USD
Do you need bulk/larger quantities?
Replaces Prod. #: ALX-270-209

Antitumor reagent. Topoisomerase II inhibitor. Induces apoptosis by FasL. Activates p53 resulting in upregulated expression of TRAIL-R2 (DR5) and Bak to overcome TRAIL resistance in Bax-deficient human colon carcinoma cancer cells.

Product Details

Alternative Name:4-Desmethylepipodophyllotoxin 9-(4,6-O-ethylidene)-β-D-glucopyranoside, VP-16-213
Source:Semisynthetic derivative of podophyllotoxin.
MI:14: 3886
Purity:≥95% (HPLC)
Appearance:White to off-white powder.
Solubility:Soluble in DMSO, dimethyl formamide, ethyl ether or chloroform:methanol (1:1); slightly soluble in methanol or acetone; insoluble in water.
Shipping:Ambient Temperature
Long Term Storage:Ambient
Use/Stability:Store solutions in DMSO at 4°C. For long term storage prepare aliquots and store at -20°C.
Handling:Protect from light and moisture.
Regulatory Status:RUO - Research Use Only
Please mouse over

Product Literature References

Pregnancy-associated plasma protein-A (PAPP-A) is a key component of an interactive cellular mechanism promoting pulmonary fibrosis: L.K. Bale, et al.; J. Cell. Physiol. 237, 2220 (2022), Abstract;
Use of transcriptomics in hazard identification and next generation risk assessment: A case study with clothianidin: H. Sprenger, et al.; Food Chem. Toxicol. 166, 113212 (2022), Abstract;
Comparing effects of CDK inhibition and E2F1/2 ablation on neuronal cell death pathways in vitro and after traumatic brain injury: T.G. Aubrecht, et al.; Cell Death Dis. 9, 1121 (2018), Abstract; Full Text
Direct modification of the 5-HT3 receptor current by some anticancer drugs: Y. Nakamura, et al.; Eur. J. Pharmacol. 821, 21 (2017), Abstract;
Pyroptosis and apoptosis pathways engage in bidirectional crosstalk in monocytes and macrophages: C.Y. Taabazuing, et al.; Cell Chem. Biol. 24, 507 (2017), Abstract; Full Text
Regulation of hepatic cholesteryl ester transfer protein expression and reverse cholesterol transport by inhibition of DNA topoisomerase II: M. Liu, et al.; J. Biol. Chem. 290, 14418 (2015), Application(s): Cell Culture, Abstract; Full Text
The p53 binding protein PDCD5 is not rate-limiting in DNA damage induced cell death: F. J. Bock, et al.; Sci. Rep. 5, 11268 (2015), Application(s): Cell Culture, Abstract; Full Text
The antiviral adaptor proteins Cardif and Trif are processed and inactivated by caspases: M. Rebsamen, et al.; Cell Death Differ. 15, 1804 (2008), Abstract;
Etoposide, topoisomerase II and cancer: E.L. Baldwin & N. Osheroff; Curr. Med. Chem. Anticancer Agents 5, 363 (2005), Review, Abstract;
Etoposide: discovery and medicinal chemistry: P. Meresse, et al.; Curr. Med. Chem. 11, 2443 (2004), Review, Abstract;
Cell cycle phase specificity in the potentiation of etoposide-induced DNA damage and apoptosis by KN-62, an inhibitor of calcium-calmodulin- dependent enzymes: M. Aoyama, et al.; Biochem. Pharmacol. 61, 49 (2001), Abstract;
Deacetylase activity associates with topoisomerase II and is necessary for etoposide-induced apoptosis: C.A. Johnson, et al.; J. Biol. Chem. 276, 4539 (2001), Abstract; Full Text
In vitro topo II-DNA complex accumulation and cytotoxicity of etoposide in leukaemic cells from patients with acute myelogenous and chronic lymphocytic leukaemia: Y. Wang, et al.; Leuk. Res. 25, 133 (2001), Abstract;
A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis: C. Mascaux, et al.; Lung Cancer 30, 23 (2000), Abstract;
Distinct pathways for stimulation of cytochrome c release by etoposide: J.D. Robertson, et al.; J. Biol. Chem. 275, 32438 (2000), Abstract; Full Text
Early caspase activation in leukemic cells subject to etoposide-induced G2-M arrest: evidence of commitment to apoptosis rather than mitotic cell death: R.J. Sleiman & B.W. Stewart; Clin. Cancer Res. 6, 3756 (2000), Abstract; Full Text
Etoposide-induced apoptosis is not associated with the fas pathway in acute myeloblastic leukemia cells: T. Siitonen, et al.; Leuk. Res. 24, 281 (2000), Abstract;
Ordering of ceramide formation, caspase activation, and Bax/Bcl-2 expression during etoposide-induced apoptosis in C6 glioma cells: M. Sawada, et al.; Cell Death Differ. 7, 761 (2000), Abstract;
Etoposide sensitivity of human prostatic cancer cell lines PC-3, DU 145 and LNCaP: M. Salido, et al.; Histol. Histopathol. 14, 125 (1999), Abstract;
Etoposide: four decades of development of a topoisomerase II inhibitor: K.R. Hande; Eur. J. Cancer 34, 1514 (1998), Abstract;
Etoposide: twenty years later: J.D. Hainsworth & F.A. Greco; Ann. Oncol. 6, 325 (1995), Abstract;
Review of current clinical experience with prolonged (oral) etoposide in cancer treatment: R.S. de Jong, et al.; Anticancer Res. 15, 2319 (1995), Abstract;
Dexamethasone and etoposide induce apoptosis in rat thymocytes from different phases of the cell cycle: H.O. Fearnhead, et al.; Biochem. Pharmacol. 48, 1073 (1994), Abstract;
The podophyllotoxin derivatives VP16-213 and VM26: B.F. Issell; Cancer Chemother. Pharmacol. 7, 73 (1982), Abstract;

Related Literature

Download as PDF

All new literature pieces